非处方药市场按药品类型、产品形式、分销管道、年龄层和最终用户划分－2025-2030 年全球预测

非处方药 (OTC) 市场规模预计在 2024 年达到 525.2 亿美元，在 2025 年达到 567.5 亿美元，复合年增长率为 8.68%，在 2030 年达到 865.8 亿美元。

主要市场统计数据
基准年2024年	525.2亿美元
预计2025年	567.5亿美元
预测年份 2030	865.8亿美元
复合年增长率（%）	8.68%

非处方药产业正在经历前所未有的变革，这得益于消费行为的根本性转变、监管机构对自我护理的支持以及技术的快速变革时期。虽然实体店分销曾经是常态，但如今，由于人口结构多样化，包括注重健康的千禧世代、战后婴儿潮世代以及开发中地区新兴的中产阶级，非处方药产业正在向多元化发展，包括数位和混合管道。近年来，对预防性健康解决方案的需求激增，迫使製造商不断创新配方和包装设计，优先考虑便利性和依从性。

在这种动态环境中，监管机构的职责已发生演变，以适应快速转换计划和统一的标籤指南，这些指南优先考虑安全性，同时降低市场准入门槛。因此，市场参与企业正在重新思考其产品开发、供应链韧性和全通路行销的方法。直接面向消费者的广告和与网红的伙伴关係正在进一步加速产品知名度的提升，并使利基品牌能够挑战现有品牌。

本执行摘要对动盪不安却充满机会的非处方药市场进行了全面的介绍。它概述了关键的市场驱动因素、关键的监管发展以及塑造产业新篇章的策略必要事项。读者将清楚了解变革趋势、细分考虑、区域动态、竞争定位以及对持续成长和竞争差异化至关重要的可行建议。

数位医疗的整合、不断变化的监管环境以及不断变化的消费者偏好正在推动非处方药市场的变革

非处方药市场正在经历重大变革时期，这得益于数位医疗平台的整合、监管的加强以及消费者期望的不断变化。远端医疗应用程式和人工智慧症状检查器正在简化病人历程，而行动医疗钱包和订阅模式则将个人化的护理方案直接送到患者家中。此外，虚拟药局的兴起正在颠覆传统的零售模式，透过数据主导的推荐，实现更快的履约和更深入的消费者互动。

检验2025 年美国关税对非处方药供应链、定价结构和州际贸易动态的累积影响

2025年美国新关税的实施，正在对非处方药供应链、定价策略和贸易流量产生累积影响。这些针对关键药物成分和包装零件的关税，给依赖从现有原料药（API）进口的製造商带来了额外的成本压力。因此，许多公司利润率受到挤压，被迫重新评估筹资策略。

透过对非处方药类型、剂型、通路、年龄层和最终用户概况进行详细細項分析，发现成长机会

详细了解市场细分可以发现跨治疗类别、剂型、分销管道、年龄层和最终用户概况的定位机会。按药物类型，感冒、咳嗽和过敏类别细分为抗组织胺、止咳药和减充血剂，以反映季节性和慢性病的不同需求模式。皮肤科和护肤包括痤疮药物、抗真菌药膏和皮肤保护剂，可满足美容和临床使用案例。消化器官系统产品包括从制酸剂到止泻和泻药，可用于一次性和长期胃肠道管理。护耳保健满足感官舒适和卫生需求，而疼痛缓解包括非类固醇镇痛药到局部止痛药。最后，维生素和补充剂继续受到预防性健康促进倡导者的强劲需求。

全面的区域视角，重点介绍美洲、中东和非洲以及亚太地区非处方药产业的市场动态

美洲、中东和非洲以及亚太地区的非处方药市场动态差异巨大，每个地区都面临独特的挑战和成长催化剂。美洲是一个成熟的市场，人均非处方药消费量高，并透过在超级市场和直销数位平台拓展自有品牌不断创新。在北美，监管协调促进了跨境产品上市，而消费者的期望则侧重于循证配方和以生活方式为导向的自我护理。

对影响非处方药市场格局的主要製药和保健公司的策略竞争考察

非处方药市场的竞争格局由全球製药巨头、专注于消费者保健的专业製造商以及敏捷的区域企业共同塑造。知名的跨国公司凭藉多元化的产品组合、持续的研发投入以及覆盖传统零售和数位通路的广泛分销网络，保持着领先地位。跨国公司的规模使其能够提高采购效率并快速实现全球上市，从而为规模较小的参与企业设置了显着的进入障碍。

实用且具前瞻性的建议，使行业领导者能够利用非处方药市场的新兴趋势

产业领导者若想在不断发展的非处方药市场中获利，必须制定一个多层面的策略议程，将数位创新、监管敏捷性和消费者亲密度融为一体。首先，将高阶分析技术整合到消费者互动平台中，可实现个人化建议、精准促销和完善的产品开发蓝图。增强的数据能力还支援动态定价模型，能够即时响应不断变化的投入成本和竞争压力。

我们的综合研究途径利用初步研究和二次资料分析，为非处方药产业提供客观的见解

研究采用综合调查方法，将一手资料研究与二手资料分析和严格的专家检验相结合，以提供可靠、公正的见解。一手资料研究包括与製药和消费者保健公司高阶主管、供应链专家、监管顾问和数位健康创新者进行结构化访谈。这些访谈提供了关于策略挑战、投资重点和新兴市场机会的第一手观点。

总结策略展望，整合关键市场驱动因素和新兴趋势，塑造非处方药产业的未来成长轨迹

摘要：非处方药市场正处于数位颠覆、法规不断演变和消费者期望不断变化的关键十字路口。关税压力、细分市场差异和区域动态的相互作用，凸显了供应链韧性和策略敏捷性的重要性。竞争优势取决于如何利用数据主导的洞察、与监管机构建立伙伴关係，以及针对不同治疗类别和人群提供有针对性的产品。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章市场动态

• 消费者对整合虚拟就诊和非处方药购买功能的数位健康平台的偏好日益增加
• 注重健康的千禧世代推动植物来源和有机非处方补充剂的成长
• 个人化药物套餐和订阅服务在慢性非处方药使用者中的普及度不断提升
• 监管变化对网路药局含假麻黄碱鼻减充血剂可得性的影响
• 疫情期间，含有接骨木果、维生素 C 和锌的免疫支持非处方药需求激增
• 扩大自有品牌非处方止痛药的市场，在价格和针对性疼痛管理处方方面竞争

第六章 市场洞察

• 波特五力分析
• PESTEL分析

第七章 2025年美国关税的累积影响

第八章非处方药市场（依药品类型）

• 感冒、咳嗽和过敏药
  • 抗组织胺药
  • 止咳药
  • 鼻减充血剂
• 皮肤科/护肤
  • 痤疮治疗
  • 抗霉菌药膏
  • 皮肤屏障
• 消化器官系统健康
  • 制酸剂
  • 止泻
  • 泻药
• 眼耳护理
• 止痛药
• 维生素和补充剂

第九章非处方药市场（依产品类型）

• 胶囊
• 液体/糖浆
• 粉末
• 喷
• 栓剂
• 药片
• 外用乳霜/软膏/凝胶

第十章非处方药市场（依分销管道）

• 离线
  • 药局和药局
  • 超级市场和大卖场
• 在线的

第 11 章非处方药市场（依年龄层）

• 成人
• 老年人
• 孩子们

第 12 章非处方药市场（依最终使用者）

• 医护人员
• 个人消费者
• 机构用户

13.美洲非处方药市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 阿根廷

第 14 章：欧洲、中东和非洲非处方药市场

• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 阿拉伯聯合大公国
• 沙乌地阿拉伯
• 南非
• 丹麦
• 荷兰
• 卡达
• 芬兰
• 瑞典
• 奈及利亚
• 埃及
• 土耳其
• 以色列
• 挪威
• 波兰
• 瑞士

15. 亚太地区非处方药市场

• 中国
• 印度
• 日本
• 澳洲
• 韩国
• 印尼
• 泰国
• 菲律宾
• 马来西亚
• 新加坡
• 越南
• 台湾

第十六章竞争格局

• 2024年市场占有率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cipla Limited
  • Dr. Reddy's Laboratories Inc.
  • Genomma group
  • GSK plc
  • Hisamitsu Pharmaceutical Co., Inc.
  • Johnson & Johnson Services, Inc.
  • LNK International, Inc.
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Pierre Fabre SA
  • PL Developments LLC
  • Procter & Gamble Manufacturing Company
  • Reckitt Benckiser LLC
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Taisho Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd
  • The Mentholatum Company, Inc.
  • Tris Pharma, Inc.
  • Viatris Inc.
  • Worwag Pharma GmbH & Co. KG
  • Zentiva Group, as

第十七章 研究人工智慧

第十八章 研究统计

第十九章 研究联络人

第二十章 研究报导

第21章 附录

The Over The Counter Drugs Market was valued at USD 52.52 billion in 2024 and is projected to grow to USD 56.75 billion in 2025, with a CAGR of 8.68%, reaching USD 86.58 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024]	USD 52.52 billion
Estimated Year [2025]	USD 56.75 billion
Forecast Year [2030]	USD 86.58 billion
CAGR (%)	8.68%

The over-the-counter drug sector has entered a period of unprecedented transformation, driven by fundamental shifts in consumer behavior, regulatory support for self-care, and rapid technological advances. Once dominated by brick-and-mortar distribution, the landscape now spans a spectrum of digital and hybrid channels that cater to a demographic blend of health-conscious millennials, aging baby boomers, and emerging middle classes in developing regions. Recent years have seen a surge in demand for preventive wellness solutions, prompting manufacturers to innovate with novel formulations and packaging designs that emphasize convenience and adherence.

Amid this dynamic environment, the role of regulatory agencies has evolved to accommodate expedited switch programs and harmonized labeling guidelines that prioritize safety while reducing barriers for market entry. Consequently, industry participants are recalibrating their approaches to product development, supply chain resilience, and omnichannel marketing. The influence of direct-to-consumer advertising and influencer partnerships has further accelerated product visibility, enabling niche brands to challenge established incumbents.

This executive summary provides a cohesive introduction to the volatile yet opportunity-rich over-the-counter drug landscape. It outlines the key market drivers, pivotal regulatory developments, and strategic imperatives shaping the industry's next chapter. Readers will gain clarity on transformative trends, segmentation insights, regional dynamics, competitive positioning, and actionable recommendations essential for sustained growth and competitive differentiation.

Transformative Shifts Reshaping the Over-the-Counter Drug Landscape Driven by Digital Health Integration, Regulatory Changes, and Changing Consumer Preferences

The over-the-counter drug market is undergoing profound transformative shifts, propelled by the integration of digital health platforms, intensified regulatory changes, and evolving consumer expectations. Telemedicine applications and AI-driven symptom checkers now streamline the purchase journey, while mobile health wallets and subscription models offer personalized care regimens directly to patients' homes. Moreover, the proliferation of virtual pharmacies has disrupted traditional retail models, enabling faster fulfillment and deeper consumer engagement through data-driven recommendations.

Parallel to these digital innovations, regulatory agencies across key markets have implemented reforms to expedite switch-to-OTC processes and standardize safety protocols. These changes have reduced the time and cost associated with bringing new therapies to over-the-counter status, encouraging firms to allocate greater resources to clinical research and real-world evidence generation. In turn, the market has seen an influx of once-prescription treatments, expanding therapeutic options in dermatology, gastrointestinal health, and respiratory care.

Concurrently, consumer preferences are shifting toward clean-label formulations, sustainable packaging, and transparent sourcing practices. Health-conscious shoppers are increasingly scrutinizing ingredient lists and favoring brands that demonstrate environmental stewardship. This confluence of digital advancement, regulatory alignment, and heightened consumer awareness is redefining competitive advantage in the OTC drug arena, compelling stakeholders to adopt agile strategies that balance innovation with compliance and brand authenticity.

Examining the Cumulative Impact of United States Tariffs in 2025 on Over-the-Counter Drug Supply Chains, Pricing Structures, and Interstate Trade Dynamics

The implementation of new United States tariff measures in 2025 has exerted a cumulative impact on over-the-counter drug supply chains, pricing strategies, and trade flows. These levies, targeting key pharmaceutical ingredients and packaging components, have introduced additional cost pressures on manufacturers reliant on imported active pharmaceutical ingredients (APIs) from established chemical hubs. As a result, many companies have experienced margin compression and have been compelled to reassess procurement strategies.

In response, stakeholders have accelerated efforts to develop localized API production capabilities and form strategic alliances with domestic suppliers. Inventory management practices have also adapted, with firms increasing safety stock levels to buffer against tariff-induced disruptions. Additionally, dynamic pricing models have emerged, enabling swift adjustment of consumer-facing prices to reflect input cost fluctuations while preserving affordability.

Beyond supply chain realignment, the tariff landscape has stimulated a broader reevaluation of global sourcing footprints. Companies are diversifying alternative manufacturing locations across Asia-Pacific and Latin America to mitigate exposure. These strategic shifts are enhancing resilience but require careful navigation of regulatory approvals and quality standards. Ultimately, the tariff environment of 2025 has catalyzed a wave of strategic realignments that are redefining competitive positioning and supply chain configurations within the over-the-counter drug market.

Unlocking Growth Opportunities Through In-Depth Segmentation Analysis of Over-the-Counter Drug Types, Forms, Channels, Age Groups, and End-User Profiles

A nuanced understanding of market segmentation reveals targeted opportunities across therapeutic categories, dosage forms, distribution channels, demographic cohorts, and end-user profiles. In the realm of drug types, the cold, cough, and allergy category subdivides into antihistamines, cough suppressants, and decongestants, reflecting differentiated demand patterns across seasonal and chronic conditions. Dermatology and skin care encompasses acne treatments, antifungal creams, and skin protectants, catering to both cosmetic and clinical use cases. Digestive health products range from antacids to anti-diarrheal remedies and laxatives, responding to episodic and long-term gastrointestinal management. Eye and ear care solutions address sensory comfort and hygiene needs, while pain relief medications span nonsteroidal analgesics and topical analgesic formulations. Finally, vitamins and supplements continue to enjoy robust demand from preventive wellness advocates.

Product form segmentation further illuminates consumer preferences, encompassing capsules, liquids and syrups, powders, sprays, suppositories, tablets and pills, as well as topical creams, ointments, and gels. Each format aligns with specific administration considerations, such as pediatric dosing comfort, geriatric swallowing ease, or localized delivery.

Distribution channels exhibit a bifurcation between offline and online pathways, with offline channels structured around pharmacies, drug stores, supermarkets, and hypermarkets that emphasize immediate accessibility. Online channels leverage e-commerce platforms and direct-to-consumer portals, facilitating subscription offerings and telehealth integration.

Demographic segmentation underscores divergent needs among adult, geriatric, and pediatric populations, each demanding tailored formulations, dosage strengths, and packaging ergonomics. Similarly, end-user segmentation distinguishes healthcare professionals prescribing or recommending OTC therapies, individual consumers driving retail purchases, and institutional users such as hospitals, long-term care facilities, and corporate wellness programs procuring products in bulk. This layered segmentation framework enables precision targeting of product portfolios, marketing strategies, and supply chain allocations.

Comprehensive Regional Perspective Highlighting Market Dynamics Across Americas, Europe Middle East & Africa, and Asia-Pacific Over-the-Counter Drug Sectors

Regional dynamics in the over-the-counter drug market vary substantially across the Americas, Europe Middle East & Africa, and Asia-Pacific, each presenting unique challenges and growth catalysts. In the Americas, a mature market characterized by high per-capita OTC consumption continues to innovate through private-label expansions in supermarkets and direct-to-consumer digital platforms. Regulatory harmonization efforts in North America facilitate cross-border product launches, while consumer expectations center on evidence-based formulations and lifestyle-oriented self-care routines.

The Europe Middle East & Africa region encompasses a broad array of regulatory environments, distribution infrastructures, and economic conditions. Western Europe's advanced regulatory frameworks and robust pharmacy networks support rapid adoption of novel OTC switches, whereas emerging economies in Eastern Europe and the Middle East prioritize affordability and access through generic alternatives and multinational partnerships. In Africa, the rise of mobile health initiatives and localized manufacturing hubs is gradually improving product availability and driving interest in mobile pharmacies and e-health platforms.

In contrast, Asia-Pacific stands out as the fastest-growing regional market, fuelled by rising disposable incomes, urbanization, and expanding healthcare access. Countries in East and Southeast Asia are witnessing surges in online pharmacy usage and cross-border purchases, while South Asia's dense population base accelerates demand for cost-effective self-care solutions. Collaborative ventures between domestic innovators and global players are enhancing technology transfer, creating a dynamic environment for product innovation and regulatory advancement.

Strategic Competitive Insights into Leading Pharmaceutical and Consumer Healthcare Companies Shaping the Over-the-Counter Drug Market Landscape

The competitive landscape of the over-the-counter drug market is shaped by global pharmaceutical giants, specialized consumer healthcare manufacturers, and agile regional players. Prominent multinational corporations maintain leadership through diversified portfolios, continuous R&D investment, and expansive distribution networks that span both traditional retail and digital channels. Their scale enables procurement efficiencies and rapid global launch capabilities, creating significant barriers for smaller entrants.

Meanwhile, niche innovators and private-label purveyors have carved out differentiation by focusing on natural and botanical formulations, premium wellness positioning, and direct engagement with consumer communities. These companies leverage e-commerce analytics and personalized marketing campaigns to gain traction in specific segments such as dermatology, digestive health, and nutritional supplements.

Regional champions in emerging markets are also gaining prominence by tailoring product offerings to local preferences and regulatory frameworks. Some have optimized cost structures through regional manufacturing hubs and strategic alliances with contract development and manufacturing organizations. Collectively, these competitive approaches underscore the importance of agility, brand authenticity, and supply chain resilience in securing sustainable market share.

Practical and Forward-Looking Recommendations Empowering Industry Leaders to Capitalize on Emerging Trends in Over-the-Counter Drug Markets

Industry leaders seeking to capitalize on the evolving over-the-counter drug market must adopt a multipronged strategic agenda that blends digital innovation, regulatory agility, and consumer intimacy. Firstly, integrating advanced analytics into consumer engagement platforms will enable personalized recommendations, targeted promotions, and refined product development roadmaps. Enhanced data capabilities will also support dynamic pricing models that adjust in real time to input cost fluctuations and competitive pressures.

Secondly, firms should pursue localized manufacturing partnerships and invest in onshore API production to mitigate tariff exposure and reduce supply chain complexity. Developing contingency plans with alternate suppliers and maintaining strategic stock reserves will further enhance resilience against geopolitical disruptions.

Thirdly, expanding into adjacent wellness categories-such as nutraceuticals, functional foods, and digital therapeutics-can unlock cross-selling synergies and attract health-oriented consumers. Collaborations with telehealth providers and integration with health monitoring devices will position organizations at the intersection of prevention and treatment.

Finally, embedding sustainability principles across product life cycles, from ingredient sourcing to packaging design, will resonate with environmentally conscious consumers and align with emerging regulatory mandates. By prioritizing these actionable recommendations, industry leaders can strengthen market positioning and drive long-term, profitable growth.

Comprehensive Research Approach Leveraging Primary Interviews and Secondary Data Analysis to Deliver Unbiased Insights into Over-the-Counter Drug Sector

This research draws upon a comprehensive methodology that synthesizes primary interviews, secondary data analysis, and rigorous expert validation to ensure robust and unbiased insights. Primary research involved structured interviews with senior executives from pharmaceutical and consumer healthcare companies, supply chain specialists, regulatory consultants, and digital health innovators. These conversations provided firsthand perspectives on strategic challenges, investment priorities, and emerging market opportunities.

Secondary research encompassed a systematic review of regulatory filings, industry periodicals, corporate annual reports, and technical white papers. Publicly available data from government agencies and trade associations was triangulated with proprietary sources to enhance data accuracy and contextual depth. Quantitative analyses employed advanced statistical techniques to identify consumption patterns, channel shifts, and demographic influences across multiple geographies.

Finally, an expert validation process convened cross-functional industry advisors to critique preliminary findings, refine segmentation frameworks, and vet strategic recommendations. This iterative approach ensured that conclusions reflect the latest market developments and operational realities, offering decision-makers a credible foundation for strategic planning.

Concluding Strategic Perspectives Synthesizing Key Market Drivers and Emerging Trends Shaping Future Growth Trajectories in Over-the-Counter Drug Industry

In summary, the over-the-counter drug market stands at a pivotal juncture defined by digital disruption, regulatory evolution, and shifting consumer expectations. The interplay of tariff pressures, segmentation nuances, and regional dynamics underscores the importance of supply chain resilience and strategic agility. Competitive success will hinge on the ability to harness data-driven insights, cultivate regulatory partnerships, and deliver targeted offerings across therapeutic categories and demographic groups.

As market participants navigate this complex environment, those who embrace innovation in manufacturing, distribution, and marketing will secure the greatest advantage. Proactive investments in localized production, sustainable practices, and consumer personalization will strengthen brand loyalty and foster long-term growth. By internalizing the strategic recommendations outlined herein, organizations can chart a clear path forward and translate market intelligence into differentiated value propositions.

Ultimately, the insights presented in this summary provide a strategic roadmap for executives, investors, and stakeholders aiming to capitalize on the accelerating momentum within the over-the-counter drug sector. The confluence of emerging technologies, consumer empowerment, and regulatory reforms offers a fertile landscape for innovation and competitive advancement.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Increasing consumer preference for digital health platforms integrating virtual consultations with OTC medication purchases
• 5.2. Accelerated growth in plant-based and organic OTC supplements driven by wellness-focused millennial demographics
• 5.3. Rising adoption of personalized dosage packaging and subscription services for chronic OTC medication users
• 5.4. Impact of regulatory shifts on accessibility of pseudoephedrine-containing decongestants in online pharmacies
• 5.5. Surge in demand for immune support OTC products fortified with elderberry, vitamin C, and zinc during viral seasons
• 5.6. Expansion of private label OTC pain relievers competing on price and targeted pain management formulations

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Over The Counter Drugs Market, by Drug Type

• 8.1. Introduction
• 8.2. Cold, Cough, & Allergy Medications
  • 8.2.1. Antihistamines
  • 8.2.2. Cough Suppressants
  • 8.2.3. Decongestants
• 8.3. Dermatology & Skin Care
  • 8.3.1. Acne Treatments
  • 8.3.2. Antifungal Creams
  • 8.3.3. Skin Protectants
• 8.4. Digestive Health
  • 8.4.1. Antacids
  • 8.4.2. Anti-diarrheal
  • 8.4.3. Laxatives
• 8.5. Eye & Ear Care
• 8.6. Pain Relief Medications
• 8.7. Vitamins & Supplements

9. Over The Counter Drugs Market, by Product Form

• 9.1. Introduction
• 9.2. Capsules
• 9.3. Liquids/Syrups
• 9.4. Powders
• 9.5. Sprays
• 9.6. Suppositories
• 9.7. Tablets/Pills
• 9.8. Topical Creams/Ointments/Gels

10. Over The Counter Drugs Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Offline
  • 10.2.1. Pharmacies & Drug Stores
  • 10.2.2. Supermarkets & Hypermarkets
• 10.3. Online

11. Over The Counter Drugs Market, by Age Group

• 11.1. Introduction
• 11.2. Adult
• 11.3. Geriatric
• 11.4. Pediatric

12. Over The Counter Drugs Market, by End-user

• 12.1. Introduction
• 12.2. Healthcare Professionals
• 12.3. Individual Consumers
• 12.4. Institutional Users

13. Americas Over The Counter Drugs Market

• 13.1. Introduction
• 13.2. United States
• 13.3. Canada
• 13.4. Mexico
• 13.5. Brazil
• 13.6. Argentina

14. Europe, Middle East & Africa Over The Counter Drugs Market

• 14.1. Introduction
• 14.2. United Kingdom
• 14.3. Germany
• 14.4. France
• 14.5. Russia
• 14.6. Italy
• 14.7. Spain
• 14.8. United Arab Emirates
• 14.9. Saudi Arabia
• 14.10. South Africa
• 14.11. Denmark
• 14.12. Netherlands
• 14.13. Qatar
• 14.14. Finland
• 14.15. Sweden
• 14.16. Nigeria
• 14.17. Egypt
• 14.18. Turkey
• 14.19. Israel
• 14.20. Norway
• 14.21. Poland
• 14.22. Switzerland

15. Asia-Pacific Over The Counter Drugs Market

• 15.1. Introduction
• 15.2. China
• 15.3. India
• 15.4. Japan
• 15.5. Australia
• 15.6. South Korea
• 15.7. Indonesia
• 15.8. Thailand
• 15.9. Philippines
• 15.10. Malaysia
• 15.11. Singapore
• 15.12. Vietnam
• 15.13. Taiwan

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Amneal Pharmaceuticals LLC
  • 16.3.2. Aurobindo Pharma Limited
  • 16.3.3. Bayer AG
  • 16.3.4. Cipla Limited
  • 16.3.5. Dr. Reddy's Laboratories Inc.
  • 16.3.6. Genomma group
  • 16.3.7. GSK plc
  • 16.3.8. Hisamitsu Pharmaceutical Co., Inc.
  • 16.3.9. Johnson & Johnson Services, Inc.
  • 16.3.10. LNK International, Inc.
  • 16.3.11. Novartis AG
  • 16.3.12. Perrigo Company plc
  • 16.3.13. Pfizer Inc.
  • 16.3.14. Pierre Fabre S.A
  • 16.3.15. PL Developments LLC
  • 16.3.16. Procter & Gamble Manufacturing Company
  • 16.3.17. Reckitt Benckiser LLC
  • 16.3.18. Sanofi S.A.
  • 16.3.19. Sun Pharmaceutical Industries Limited
  • 16.3.20. Taisho Pharmaceutical Co., Ltd.
  • 16.3.21. Teva Pharmaceutical Industries Ltd
  • 16.3.22. The Mentholatum Company, Inc.
  • 16.3.23. Tris Pharma, Inc.
  • 16.3.24. Viatris Inc.
  • 16.3.25. Worwag Pharma GmbH & Co. KG
  • 16.3.26. Zentiva Group, a.s.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

• FIGURE 1. OVER THE COUNTER DRUGS MARKET RESEARCH PROCESS
• FIGURE 2. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 3. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 4. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
• FIGURE 6. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2024 VS 2030 (%)
• FIGURE 8. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 10. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
• FIGURE 12. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
• FIGURE 14. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 15. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 16. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 17. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 18. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 21. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 22. ASIA-PACIFIC OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 23. OVER THE COUNTER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 24. OVER THE COUNTER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
• FIGURE 25. OVER THE COUNTER DRUGS MARKET: RESEARCHAI
• FIGURE 26. OVER THE COUNTER DRUGS MARKET: RESEARCHSTATISTICS
• FIGURE 27. OVER THE COUNTER DRUGS MARKET: RESEARCHCONTACTS
• FIGURE 28. OVER THE COUNTER DRUGS MARKET: RESEARCHARTICLES

LIST OF TABLES

• TABLE 1. OVER THE COUNTER DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
• TABLE 5. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 7. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 9. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 11. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 13. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 15. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COUGH SUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 17. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DECONGESTANTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DECONGESTANTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 19. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
• TABLE 21. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 23. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ACNE TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ACNE TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 25. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTIFUNGAL CREAMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTIFUNGAL CREAMS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 27. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SKIN PROTECTANTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SKIN PROTECTANTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 29. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
• TABLE 31. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, BY REGION, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, BY REGION, 2025-2030 (USD MILLION)
• TABLE 33. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTACIDS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 35. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTI-DIARRHEAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ANTI-DIARRHEAL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 37. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY LAXATIVES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY LAXATIVES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 39. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
• TABLE 41. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY EYE & EAR CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY EYE & EAR CARE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 43. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PAIN RELIEF MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PAIN RELIEF MEDICATIONS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 45. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY VITAMINS & SUPPLEMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY VITAMINS & SUPPLEMENTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 47. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 49. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 51. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY LIQUIDS/SYRUPS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY LIQUIDS/SYRUPS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 53. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY POWDERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 55. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SPRAYS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 57. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 59. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY TABLETS/PILLS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY TABLETS/PILLS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 61. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY TOPICAL CREAMS/OINTMENTS/GELS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY TOPICAL CREAMS/OINTMENTS/GELS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 63. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 65. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 67. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PHARMACIES & DRUG STORES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PHARMACIES & DRUG STORES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 69. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SUPERMARKETS & HYPERMARKETS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY SUPERMARKETS & HYPERMARKETS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 71. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 73. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 75. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 77. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
• TABLE 79. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
• TABLE 81. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
• TABLE 83. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 85. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY HEALTHCARE PROFESSIONALS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 87. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY INDIVIDUAL CONSUMERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY INDIVIDUAL CONSUMERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 89. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY INSTITUTIONAL USERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL OVER THE COUNTER DRUGS MARKET SIZE, BY INSTITUTIONAL USERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 91. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 92. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 93. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 94. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
• TABLE 95. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
• TABLE 96. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
• TABLE 97. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
• TABLE 98. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
• TABLE 99. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 100. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 101. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 102. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 103. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 104. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 105. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 106. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 107. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 108. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 109. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 110. AMERICAS OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 111. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 112. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 113. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 114. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
• TABLE 115. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
• TABLE 116. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
• TABLE 117. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
• TABLE 118. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
• TABLE 119. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 120. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 121. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 122. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 123. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 124. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 125. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 126. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 127. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 128. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 129. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
• TABLE 130. UNITED STATES OVER THE COUNTER DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
• TABLE 131. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 132. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 133. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 134. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
• TABLE 135. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
• TABLE 136. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
• TABLE 137. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
• TABLE 138. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
• TABLE 139. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 140. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 141. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 142. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 143. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 144. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 145. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 146. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 147. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 148. CANADA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 149. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 150. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 151. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 152. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
• TABLE 153. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
• TABLE 154. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
• TABLE 155. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
• TABLE 156. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
• TABLE 157. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 158. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 159. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 160. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 161. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 162. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 163. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 164. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 165. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 166. MEXICO OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 167. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 168. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 169. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 170. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
• TABLE 171. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
• TABLE 172. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
• TABLE 173. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
• TABLE 174. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
• TABLE 175. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 176. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 177. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 178. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 179. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 180. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 181. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 182. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 183. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 184. BRAZIL OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 185. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 186. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 187. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 188. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
• TABLE 189. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
• TABLE 190. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
• TABLE 191. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
• TABLE 192. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
• TABLE 193. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 194. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 195. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 196. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 197. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 198. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 199. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 200. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 201. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 202. ARGENTINA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 204. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 205. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 206. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
• TABLE 207. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
• TABLE 208. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA OVER THE COUNTER DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 223. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 224. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 225. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 226. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
• TABLE 227. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
• TABLE 228. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
• TABLE 230. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 232. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 234. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 236. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 238. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 240. UNITED KINGDOM OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 241. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 242. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 243. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 244. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
• TABLE 245. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
• TABLE 246. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
• TABLE 247. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
• TABLE 248. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
• TABLE 249. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 250. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 251. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 252. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 253. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 254. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 255. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 256. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 257. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 258. GERMANY OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 259. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 260. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 261. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 262. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
• TABLE 263. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
• TABLE 264. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
• TABLE 265. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
• TABLE 266. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
• TABLE 267. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 268. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 269. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 270. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 271. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 272. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 273. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 274. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 275. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 276. FRANCE OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 277. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 278. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 279. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 280. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
• TABLE 281. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
• TABLE 282. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
• TABLE 283. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
• TABLE 284. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
• TABLE 285. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 286. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 287. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 288. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 289. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 290. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 291. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 292. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 293. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 294. RUSSIA OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 295. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 296. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 297. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 298. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
• TABLE 299. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
• TABLE 300. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
• TABLE 301. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
• TABLE 302. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
• TABLE 303. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2018-2024 (USD MILLION)
• TABLE 304. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY PRODUCT FORM, 2025-2030 (USD MILLION)
• TABLE 305. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 306. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 307. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 308. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 309. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
• TABLE 310. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY AGE GROUP, 2025-2030 (USD MILLION)
• TABLE 311. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 312. ITALY OVER THE COUNTER DRUGS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
• TABLE 313. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
• TABLE 314. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DRUG TYPE, 2025-2030 (USD MILLION)
• TABLE 315. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2018-2024 (USD MILLION)
• TABLE 316. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY COLD, COUGH, & ALLERGY MEDICATIONS, 2025-2030 (USD MILLION)
• TABLE 317. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2018-2024 (USD MILLION)
• TABLE 318. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DERMATOLOGY & SKIN CARE, 2025-2030 (USD MILLION)
• TABLE 319. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2018-2024 (USD MILLION)
• TABLE 320. SPAIN OVER THE COUNTER DRUGS MARKET SIZE, BY DIGESTIVE HEALTH, 2025-2030 (USD MILLION)
• TABLE 321. SPAIN OVER THE COUNTER DRUGS MARKE